Shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) were up 7.3% during trading on Tuesday . The stock traded as high as $20.57 and last traded at $20.57, with a volume of 108,066 shares changing hands. The stock had previously closed at $19.17.

Several analysts have commented on ATRA shares. Jefferies Group reissued a “buy” rating and set a $25.00 price target on shares of Atara Biotherapeutics in a research report on Tuesday, August 9th. JMP Securities reissued a “buy” rating on shares of Atara Biotherapeutics in a research report on Saturday, July 9th. Canaccord Genuity reissued a “buy” rating on shares of Atara Biotherapeutics in a research report on Tuesday, June 7th. Zacks Investment Research raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 2nd. Finally, Goldman Sachs Group Inc. lowered shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating and decreased their price target for the company from $23.00 to $16.00 in a research report on Thursday, September 15th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. Atara Biotherapeutics presently has a consensus rating of “Hold” and an average price target of $26.14.

The firm’s market cap is $587.74 million. The firm has a 50-day moving average of $21.49 and a 200 day moving average of $19.99.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/atara-biotherapeutics-inc-atra-trading-up-7-3.html

Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Monday, August 8th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.61) by $0.05. Analysts expect that Atara Biotherapeutics Inc. will post ($2.85) earnings per share for the current year.

In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 7,200 shares of Atara Biotherapeutics stock in a transaction dated Friday, September 16th. The stock was sold at an average price of $19.36, for a total value of $139,392.00. Following the completion of the transaction, the chief executive officer now directly owns 229,136 shares of the company’s stock, valued at approximately $4,436,072.96. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Isaac E. Ciechanover sold 9,600 shares of Atara Biotherapeutics stock in a transaction dated Friday, July 8th. The shares were sold at an average price of $22.88, for a total value of $219,648.00. Following the completion of the transaction, the chief executive officer now directly owns 223,228 shares of the company’s stock, valued at $5,107,456.64. The disclosure for this sale can be found here. 16.10% of the stock is owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Nationwide Fund Advisors increased its position in Atara Biotherapeutics by 38.0% in the second quarter. Nationwide Fund Advisors now owns 15,110 shares of the company’s stock valued at $340,000 after buying an additional 4,159 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Atara Biotherapeutics by 44.0% in the second quarter. JPMorgan Chase & Co. now owns 90,135 shares of the company’s stock worth $2,029,000 after buying an additional 27,535 shares in the last quarter. Neuberger Berman Group LLC increased its position in shares of Atara Biotherapeutics by 18.2% in the second quarter. Neuberger Berman Group LLC now owns 629,120 shares of the company’s stock worth $14,161,000 after buying an additional 96,750 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Atara Biotherapeutics by 6,736.5% in the second quarter. PNC Financial Services Group Inc. now owns 6,563 shares of the company’s stock worth $148,000 after buying an additional 6,467 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale increased its position in shares of Atara Biotherapeutics by 23.7% in the second quarter. DekaBank Deutsche Girozentrale now owns 16,200 shares of the company’s stock worth $365,000 after buying an additional 3,100 shares in the last quarter. 75.50% of the stock is owned by institutional investors.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

5 Day Chart for NASDAQ:ATRA

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.